drugset / Trial / NCT04952155
Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IL-2 | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |